



Deliverable D7.5

PRISMAP workshops



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008571 (PRISMAP). This document reflects only the view of the author(s). The Agency is not responsible for any use that may be made of the information it contains.

Project Acronym	PRISMAP
Project Title	The European medical isotope programme: Production of high purity isotopes by mass separation
Grant Agreement No.	101008571
Topic	INFRAIA-02-2020: Integrating Activities for Starting Communities
Project start date	01 May 2021
Nature	Other
Dissemination level	Public
Due date	M54
Date of delivery	M54
Lead partner	KULeuven (replacing SCIPROM)
Contributing partners	SCIPROM, all
Authors	Thomas Elias Cocolios (KULeuven), Peter Ulrich (SCIPROM)
Reviewer	Kirsten Leufgen (SCIPROM)

Point of Contact	Thomas Elias Cocolios
Institution	KULeuven
E-mail	thomas.cocolios@kuleuven.be
Phone	+32473653950



© PRISMAP 2021. This work is licensed under a [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Revision History

Version	Date	Author	Comment
0.1	09.10.2025	Thomas Elias Cocolios	First draft
0.2	13.10.2025	Peter Ulrich, Thierry Stora, Ferid Haddad	Additional input on the different events
0.3	20.10.2025	Thomas Elias Cocolios	Consolidated version
0.9	21.10.2024	Kirsten Leufgen, Peter Ulrich	Final input on the different events, review, version for final review of the general assembly
1.0	27.10.2025	Kirsten Leufgen	Final version, approved by the general assembly

Contents

Abbreviations	5
Participant short names	5
Summary	6
1. Engaging with the scientific community	7
2. PRISMAP workshops	8
2.1 Format of the PRISMAP workshops	8
2.2 List of the PRISMAP workshops at major conferences	8
2.2.1 EANM 2021	8
2.2.2 International Symposium on Trends in Radiopharmaceuticals 2023	8
2.2.3 Auger Symposium	9
2.2.4 Workshop on radionuclide production and medical applications	9
2.2.5 EANM 2025	9
3. Other scientific meetings	9
4. Conclusions and outlook	10

Abbreviations

EANM	European Association of Nuclear Medicine
IAEA	International Atomic Energy Agency

Participant short names

CERN	European organization for nuclear research
NPL	National Physical Laboratory
PSI	Paul Scherrer Institut
CEA	Commissariat à l'énergie atomique et aux énergies alternatives
IST-ID	Associação do Instituto Superior Técnico para a IST-ID Investigação e Desenvolvimento
DTU	Danmarks Tekniske Universitet
CHUV	Centre hospitalier universitaire vaudois
GANIL	Grand Accélérateur National d'Ions Lourds
SCK CEN	Studiecentrum voor Kernenergie / Centre d'étude de l'énergie nucléaire
ARRONAX	Groupement d'intérêt public ARRONAX
ESS	European spallation source ERIC
TUM	Klinikum rechts der Isar der technischen Universität München
KULeuven	Katholieke Universiteit Leuven
MedAustron	Entwicklungs- und Betriebsgesellschaft MedAustron GmbH
SCIPROM	SCIPROM Sàrl
MUI	Medizinische Universität Innsbruck
ILL	Institut Max von Laue - Paul Langevin
JRC	JRC -Joint Research Centre- European Commission
NCBJ	Narodowe Centrum Badań Jądrowych
GSI	GSI Helmholtzzentrum für Schwerionenforschung GmbH
LU	Latvijas Universitāte
INFN	Istituto Nazionale di Fisica Nucleare
UiO	Universitetet i Oslo

Summary

PRISMAP has thoroughly engaged with the scientific community to promote its services but also to report its findings and results from its users. Some of this engagement was done through the organisation of dedicated session at major international events, in order to reach an audience that might not already be aware of PRISMAP and its services.

We have organised five such events throughout the duration of the PRISMAP project, including two at the international congress of EANM. Those events have been very successful, resulting in increased membership to the PRISMAP Community and shaping future collaborations, some of which have been concretised in the PRISMAP+ proposal.

1. Engaging with the scientific community

Besides PRISMAP's engagement to its users, our consortium has also strived to inform on its services and disseminate its findings and that of its user projects to the broad scientific community. This has been one of the pillars of the dissemination strategy within PRISMAP, which dissemination team regularly identified national and international events of relevance for our consortium and ensured proper representation at those events.

Within the scientific community, we have regularly engaged with the PRISMAP Community¹, which features those researchers who have direct interest in our findings. However, we have also further engaged with the scientific community at large through the organisation of dedicated workshops or sessions at large international events. Those events are presented below.



Keynote lecture by Jean-Pierre Pouget at the Auger Symposium in Montpellier on 7 September 2023.

¹ For more information on the PRISMAP Community, please refer to [PRISMAP D7.4](#).

2. PRISMAP workshops

2.1 Format of the PRISMAP workshops

Given the main target audience of PRISMAP is the nuclear medicine community, our dissemination strategy has targeted the annual congress of the European Association of Nuclear Medicine (EANM), as this is the flagship event of the community. When relevant, we have also joined other international events, where we could provide targeted added value while reaching out to an audience that we might otherwise not directly address.

Those dedicated sessions always featured a generic introduction to PRISMAP and its role in the European infrastructure landscape, including the presentation of our portfolio and our production and biomedical research infrastructure. It was typically followed by thematic contributions from the consortium, from the PRISMAP Industrial Board, or from PRISMAP users, as relevant to the main event where the session was held.

Most of those sessions were delivered as talks followed by discussion sessions, though we have also held networking events in the margin of such sessions, or organised a panel discussion, depending on the format best suited for the specific event.

2.2 List of the PRISMAP workshops at major conferences

2.2.1 EANM 2021

- ‘PCS-8: Novel radionuclides for theranostics on the horizon’
 - Novel Radionuclides for Theranostics - What for? (Christophe Deroose, KULeuven)
 - PRISMAP – The European medical isotope programme providing novel medical radionuclides (Thierry Stora, CERN)
 - The technical challenges to provide novel radionuclides (Mattia Manzolaro, INFN)
 - Mass separation techniques – the way to high quality? (Renata Mikolajczak, NCBJ)
 - Novel Radionuclides - Preclinical Proof of Concept (Cristina Müller, PSI)
 - Novel Radionuclides - But in Right Quality and for the Right Target (Dana Niculae, IFIN-HH, Bucharest)
 - Novel Radionuclides - What Do We Already Know in Clinical Applications? (Isabel Rauscher, TUM)
 - Novel Radionuclides - Don't Forget the Regulatory Side (Oliver Neels, HZDR, Dresden)
- Online due to the COVID-19 pandemic
- 11 October 2021
- <https://www.youtube.com/watch?v=ZOU6w1Scl3w> & <https://web.archive.org/web/20211102060444/https://eanm21.eanm.org/> for partial information
- Number of participants not disclosed

2.2.2 International Symposium on Trends in Radiopharmaceuticals 2023

- ‘Academia meets industry (PRISMAP experience)’
 - PRISMAP questionnaire to the community (Maija Radzina, LU)
 - Emerging therapeutic radioisotopes (Ulli Köster, ILL)
 - Sm-153 with high molar activity for targeted radionuclide therapy (Michiel van de Voorde, SCK CEN)
 - Challenges and opportunities in the production of RPs: industry perspective (Cristiana Gameiro-Paris, IBA, Belgium)
 - Preclinical imaging of challenging isotopes including alpha emitters for oncological applications (George Loudos, Bioemtech, Greece)
- IAEA Headquarters, Vienna International Center, Austria
- 18 April 2023, 16:00-17:30 (CET)
- Plenary session followed by a networking event
- <https://www.iaea.org/events/istr-2023>

- 70 participants

2.2.3 Auger Symposium

- ‘PRISMAP Session’
 - Production of Auger emitters in PRISMAP (Mikael Jensen, DTU)
 - Evaluation of the therapeutic potential of [Cu-64]CuCl₂ in 3D models of glioblastoma (Filipa Mendes, University of Lisbon)
 - Possibilities and options for production of Auger emitters in PRISMAP (Thierry Stora, CERN)
- Montpellier, France
- 7 September 2023, 11:45—12:30 (CET)
- In-person meeting
- <https://auger-symposium.com>
- 50 participants

2.2.4 Workshop on radionuclide production and medical applications

- ‘PRISMAP’
 - CERN – The European medical radionuclides programme (Thierry Stora, CERN)
 - The production at DTU and dispatch of research radionuclides in PRISMAP - an input to PRISMAP (Mikael Jensen, DTU)
 - Investigations and options for future involvement of ESS in the long term for medical isotopes (Luca Zanini, ESS)
- Oslo, Norway
- 14 May 2025, 09:00—10:30
- In-person meeting
- <https://www.nnrc.uio.no/english/news-and-events/events/radionuclide-production-and-medical-application.html>
- 40 participants

2.2.5 EANM 2025

- ‘PRISMAP’
 - The PRISMAP project – past & future (Thierry Stora, CERN)
 - A PRISMAP user’s experience (Eleni Gourni, Inselspital, Bern)
 - PRISMAP radionuclides – translation activities (Clemens Decristoforo, MUI)
- Barcelona, Spain
- 5 October 2025, 14:00—14:30
- EU Affair Track
- <https://eanm25.eanm.org>
- 30 participants

3. Other scientific meetings

Besides those events, PRISMAP has been strategically attending many scientific meetings that will be listed in the dissemination table of our final report. Moreover, PRISMAP has organised several scientific events to disseminate its findings, either as online webinars, public sessions to our consortium meetings, or dedicated workshops from our different work packages. The details of those events are reported in the PRISMAP [deliverable D7.4](#).

4. Conclusions and outlook

The PRISMAP consortium has engaged thoroughly with the scientific community. This engagement has culminated with the organisation of two dedicated sessions at the annual congress of EANM – one at the start of the project and one at the end of the project. Besides those, PRISMAP has organised dedicated sessions at key events to highlight the research potential offered by our infrastructure, as well as showcase some of the research breakthroughs that PRISMAP has already enabled.

Those key events have been central to the PRISMAP dissemination strategy. Their impact has been witnessed through an increase in the PRISMAP Community membership and in followers on our social media platform (LinkedIn).

Furthermore, those events have been the opportunity to challenge ourselves towards the international community. The feedback has been very positive, with international colleagues offering support and suggesting potential collaborations, some of which have shaped the PRISMAP+ consortium and its infrastructure, as submitted in September 2025 to HORIZON-INFRA-2025-01-SERV-02.